The core lymphedema business continues to grow double-digits, but the airway clearance segment's 25% revenue decline and rising operating expenses are pressuring profitability. Monitor the DME inventory transition resolution and the Flexitouch Pro 510(k) submission for catalysts in the airway clearance line.
Price Chart
Executive Summary
Tactile Medical reported Q3 2026 revenue of $91.9M (+7% YoY), slightly below the $92.0M consensus, and GAAP EPS of $0.31, below the $0.34 consensus. Net income declined to $7.2M from $8.2M a year ago, and Adjusted EBITDA was essentially flat at $14.3M. The company maintained its full-year revenue guidance of $360M-$366M but raised its Adjusted EBITDA guidance to $50M-$52M from $49M-$51M.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $91.9M, +7% YoY, vs $92.0M consensus
- GAAP diluted EPS $0.31, vs $0.34 consensus
- Net income $7.2M, down from $8.2M in Q3 2025
- Adjusted EBITDA $14.3M, flat vs $14.4M in Q3 2025
- Lymphedema product revenue $81.8M, +13% YoY
- Airway clearance product revenue $10.0M, -25% YoY due to DME inventory transition
- Gross margin expanded to 77% from 76% in Q3 2025
- Operating expenses rose 13% YoY to $60.9M
- Full-year 2026 revenue guidance maintained at $360M-$366M
- Full-year 2026 Adjusted EBITDA guidance raised to $50M-$52M from $49M-$51M
- Repurchased $6.2M of stock in Q3 2026
- Cash balance $75.1M, no outstanding borrowings
Financial Impact
Revenue miss of $0.1M vs consensus, EPS miss of $0.03 vs consensus; net income declined $1.0M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Lymphedema products | $81.8M | +13.1% |
| Airway clearance products | $10.0M | -25.1% |
Risk Factors
- Airway clearance revenue decline of 25% due to DME inventory transition may persist
- Operating expenses growing faster than revenue (13% vs 7%) compressing margins
- GAAP EPS and net income declining YoY despite revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393718 |
Track record
17 reports on TCMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.99 Now $26.37 −2.30% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $27.11 Now $26.37 −2.73% settles Feb 12
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $26.62 Now $26.37 −0.94% settles Feb 8
- Nov 6, 202610d ago 3 Neutral 2/10 Entry $26.59 Now $26.37 −0.83% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago Press Release Bearish 5/10 Viewing No price data
- Nov 2, 202614d ago 8-K Mixed 5/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Oct 19, 202628d ago Press Release Neutral 3/10 Entry $23.52 Now $26.37 +12.12% settles Jan 15
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers